Cytovia Therapeutics to present at Jefferies Cell Therapy Virtual Summit, BIO Investor Forum and New York Stem Cell Foundation Conference in October 2020
September 29, 2020 16:00 ET
|
Cytovia Therapeutics
NEW YORK, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company developing Natural Killer Cell Therapeutics, today announced that it will participate in...
Cytovia Therapeutics and NYSCF Announce Filing of Provisional Patent for iPSC-Derived NK Cells to Produce Unlimited On-Demand NK and CAR-NK Cells for the Treatment of Cancer
August 25, 2020 08:39 ET
|
Cytovia Therapeutics
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research institute today announced the filing of...
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer
June 03, 2020 13:25 ET
|
Cytovia Therapeutics
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces...
Hebrew University to Collaborate with Cytovia Therapeutics
March 18, 2020 09:00 ET
|
Cytovia Therapeutics
NEW YORK and JERUSALEM, March 18, 2020 (GLOBE NEWSWIRE) -- Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company...
CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics
January 09, 2020 08:00 ET
|
Cytovia Therapeutics
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The New York Stem Cell Foundation (NYSCF) Research Institute today announced a partnership with Cytovia Therapeutics Inc. (Cytovia) to develop new disease...
Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy
January 06, 2020 08:00 ET
|
Cytovia Therapeutics
SAN FRANCISCO and NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, a biopharmaceutical company, and the University of California, San Francisco (UCSF) announced today that they have...
Nkarta Therapeutics Reports Potent Natural Killer Cell Anti-Cancer Activity in Preclinical Tumor Model
November 09, 2018 08:00 ET
|
Nkarta
NK cell potency and persistence significantly improved using cell engineering technology60% increase in cytotoxicity observed with Nkarta NK cells relative to control NK cellsSingle in vivo...
Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients
October 22, 2018 09:20 ET
|
Celsion CORP
Analysis in peer-reviewed journal, Future Oncology, outlines the ability of GEN-1, a non-viral nanoparticle delivery system, to support persistent local production of IL-12 LAWRENCEVILLE, N.J,...
Discovery of Innate Immune Mechanisms of a Novel Microbial-based Approach for the Treatment of Lung Cancer
November 28, 2017 12:43 ET
|
Qu Biologics
VANCOUVER, British Columbia, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum
January 12, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has conducted new in vitro studies of natural killer...